Epilepsia Helsinki, full member of ERN Epicare and Division of Child Neurology, Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
BABA Center, Pediatric Research Center, Children's Hospital and Division of Neuropsychology, HUS Neurocenter, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Epilepsia Open. 2024 Aug;9(4):1393-1405. doi: 10.1002/epi4.12966. Epub 2024 May 24.
Infantile seizures cause great concern for both doctors and parents. In addition to modern neuroimaging and genetics, clinical tools helpful in predicting the course of the disease are needed. We prospectively studied the incidence, electroclinical characteristics and etiologies of epilepsy syndromes with onset before the age of 12 months and looked for prognostic determinants of outcome by age 24 months.
From February 2017 through May 2019, we recruited all eligible infants diagnosed with epilepsy at our unit. Data on electroclinical studies, genetic investigations and drug response were gathered prospectively. The infants were given a structured neurological examination (Hammersmith Infantile Neurological examination [HINE] and Griffiths scales) at predetermined intervals until age 24 months at which age neurocognitive evaluation with Bayley scales was performed.
Included were 60 infants (27 female). The mean onset age of epilepsy was 5.3 (±2.5 standard deviation) months. The incidence of epilepsy in the population-based cohort was 131 (95% confidence interval 99-172)/100 000. Epilepsy syndrome was identified in 80% and etiology in 58% of infants. Self-limited infantile epilepsy was the second most common syndrome (incidence 18/100 000) after infantile epileptic spasms syndrome. PRRT2 was the most common monogenic cause. At age 24 months, 37% of the infants had drug-resistant epilepsy (DRE) and half had a global developmental delay (GDD). Abnormal first HINE was the strongest predictor of GDD, followed by DRE and identified etiology. DRE was associated with structural etiology and GDD. Those with normal first HINE and good response to treatment had favorable outcomes, irrespective of the identified etiology.
Our results support a high incidence of self-limited epilepsy in infancy and PRRT2 as the genetic cause in the first year of life. Notwithstanding the advances in etiological discovery, we want to highlight the importance of clinical evaluation as standardized neurological examination with HINE proved a valuable tool in prognostication.
One in every 700-800 babies develop epilepsy within the first year after birth. Our study identified an epilepsy syndrome in 80% and the cause of epilepsy in 60% of the participants. By age 2 years, over one-third of the children still experienced seizures, and almost half faced significant developmental delay. Structural brain abnormalities increased the likelihood of difficult epilepsy and developmental challenges. Babies whose epilepsy was caused by a gene defect varied widely in development and response to medications. Babies with normal neurological examination at first visit, especially if their seizures stopped quickly, had favorable development.
婴儿癫痫发作令医生和家长都十分担忧。除了现代神经影像学和遗传学,还需要临床工具来帮助预测疾病的进程。我们前瞻性地研究了发病年龄在 12 个月以下的癫痫综合征的发病率、临床电生理特征和病因,并在 24 个月龄时寻找预后的决定因素。
从 2017 年 2 月至 2019 年 5 月,我们招募了在我院确诊为癫痫的所有符合条件的婴儿。前瞻性收集了临床电生理研究、遗传研究和药物反应的数据。婴儿在预定的间隔时间内接受了结构性神经系统检查(Hammersmith 婴儿神经检查[HINE]和 Griffiths 量表),直至 24 个月龄,此时进行贝利婴幼儿发展量表进行神经认知评估。
共纳入 60 名婴儿(27 名女性)。癫痫的平均发病年龄为 5.3(±2.5 标准差)个月。基于人群的队列中癫痫的发病率为 131(95%置信区间 99-172)/100000。80%的婴儿确定了癫痫综合征,58%确定了病因。自限性婴儿癫痫是继婴儿癫痫性痉挛综合征之后第二常见的综合征(发病率 18/100000)。PRRT2 是最常见的单基因病因。24 个月龄时,37%的婴儿患有耐药性癫痫(DRE),一半患有全面发育迟缓(GDD)。首次 HINE 异常是 GDD 的最强预测因素,其次是 DRE 和确定的病因。DRE 与结构性病因和 GDD 相关。首次 HINE 正常且治疗反应良好的婴儿预后良好,而不论病因是否确定。
我们的研究结果支持婴儿癫痫在出生后第一年具有较高的自限性发病率,PRRT2 是婴儿期的遗传病因。尽管在病因学发现方面取得了进展,但我们还是要强调临床评估的重要性,因为标准化的神经系统检查(HINE)已证明是一种有价值的预后工具。